Cognitive performance in Alzheimer's disease patients receiving rivastigmine for up to 5 years.
about
Rivastigmine for Alzheimer's diseaseRivastigmine for Alzheimer's diseaseRivastigmine for Alzheimer's diseaseGetReal in mathematical modelling: a review of studies predicting drug effectiveness in the real world.Treatment guidelines for Alzheimer's disease: redefining perceptions in primary care.Changes in cognitive domains during three years in patients with Alzheimer's disease treated with donepezilErrorless practice as a possible adjuvant to donepezil in Alzheimer's disease.Effects of a Rivastigmine Patch on Self-Care Activities in Patients with Alzheimer's Disease plus Cerebrovascular Disease.Predictors of sustained response to rivastigmine in patients with Alzheimer's disease: a retrospective analysis.Galantamine treatment in Alzheimer's disease: response and long-term outcome in a routine clinical setting.Predictors of long-term cognitive outcome in Alzheimer's diseaseAcetylcholine facilitates recovery of episodic memory after brain damageRivastigmine in Alzheimer's disease: Cognitive function and quality of life.A longitudinal study of risk factors for community-based home help services in Alzheimer's disease: the influence of cholinesterase inhibitor therapy.Cognitive impairment and preferences for current health.Pharmacological Treatment of Alzheimer's Disease: Is it Progressing Adequately?Once-daily transdermal rivastigmine in the treatment of Alzheimer's disease.Early identification and treatment of Alzheimer's disease: social and fiscal outcomes.Follow-up for Alzheimer patients: European Alzheimer Disease Consortium position paper.Turning principles into practice in Alzheimer's disease.Caprospinol: discovery of a steroid drug candidate to treat Alzheimer's disease based on 22R-hydroxycholesterol structure and properties.New pharmacological approaches to the cholinergic system: an overview on muscarinic receptor ligands and cholinesterase inhibitors.Prediction models for assessing long-term outcome in Alzheimer's disease: a review.A 24-week, multicentre, open evaluation of the clinical effectiveness of the rivastigmine patch in patients with probable Alzheimer's disease.Donepezil in Alzheimer's disease: what to expect after 3 years of treatment in a routine clinical setting.Could cholinesterase inhibitors be harmful over the long term?
P2860
Q24186551-C842867A-9A9C-4C8A-93A7-E83A586189F1Q24187067-36AFEEBA-9656-413E-B213-4E21EEB5CE16Q24241686-D6CD6E1D-4C43-42B0-BA7E-D7F88ED0922AQ30248472-0D11106F-AAD6-408B-AE53-2ADB03AFD335Q30443975-4F532ABD-4628-472C-A3AC-89A0AF200B4AQ33408028-6D20861C-E768-41CE-B87D-A10CC4FF7A45Q34443767-03AD71C5-F8D6-4D17-AB1E-9FC368145323Q34632737-5427425D-8C05-4948-A84D-E88A2ED8728CQ35252005-FCBE69A0-436D-4453-95F3-4F3A64E00433Q35327053-74FA11B1-2290-4458-8940-93D5307D1556Q35579243-9B5B8044-3FE0-4D2D-95D7-34A00711C205Q36330555-36BEE08B-74CF-4928-93BB-D9409D0481D1Q36663678-380845BC-F7C5-4905-A045-B27E6ACECA9AQ36723409-2EA7B9F1-83B2-4E8F-B9DF-698F1E332A6AQ37078424-3F0250EF-39AE-4754-92DA-341D98F9C150Q37198579-D6FC3B9B-D9A3-447A-89AC-F7345F3890B8Q37385577-239FE722-67B4-42A5-8F6A-9CF882543D74Q37449105-21D8E35F-EE41-4BEC-90E4-0C23D7951B3EQ37686190-0A145E98-1082-48AB-80CC-CB360C181904Q37763287-3F507AF9-603D-4125-B2A5-3AF78357C56FQ37882023-25EDAA16-6C4A-4F3C-A1C1-8248E6589DF3Q38099889-00C8366B-5697-4CA6-B295-2FAFC6F13887Q38108098-06F894C2-E591-47DE-91D9-FC2B8D9B47E4Q50799612-DBAC923B-FD52-47F2-A97D-1AEF77F47B92Q51906755-2479AF9F-05E9-49E0-B304-4610152768C1Q53324826-7D46414B-D259-44FE-941A-65ECA9785AE8
P2860
Cognitive performance in Alzheimer's disease patients receiving rivastigmine for up to 5 years.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Cognitive performance in Alzhe ...... ivastigmine for up to 5 years.
@ast
Cognitive performance in Alzhe ...... ivastigmine for up to 5 years.
@en
type
label
Cognitive performance in Alzhe ...... ivastigmine for up to 5 years.
@ast
Cognitive performance in Alzhe ...... ivastigmine for up to 5 years.
@en
prefLabel
Cognitive performance in Alzhe ...... ivastigmine for up to 5 years.
@ast
Cognitive performance in Alzhe ...... ivastigmine for up to 5 years.
@en
P2093
P1476
Cognitive performance in Alzhe ...... ivastigmine for up to 5 years.
@en
P2093
P2860
P304
P356
10.1111/J.1368-5031.2005.00524.X
P577
2005-04-01T00:00:00Z